EZH2 and neoplasm: Although there are encouraging results in HNSCC, bladder, gastric, cervical, and endometrial tumors, more studies, especially those conducted in a clinical setting, are needed to confirm the beneficial effects of a combined EZH2-targeting and cisplatin therapy in these and other tumor types and to shed light on potential mechanisms of action.